Clinical and therapeutic implications of nestin in small cell lung cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 26461193
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Nagoya City University
• Principal Investigator: Maeno Ken 名古屋市立大学, 大学院医学研究科, 講師 (10444952)
• Co-Investigator(Kenkyū-buntansha): 小栗 鉄也 名古屋市立大学, 大学院医学研究科, 准教授 (60363925) ; 小笹 裕晃 京都大学, 医学研究科, 特定助教 (80572015)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 小細胞肺癌 / ネスチン

Outline of Final Research Achievements

Nestin is a class VI intermediate filament protein expressed in stem/progenitor cells during　the development of the central nervous system. In this study, we examined whether the expression of nestin affect malignant feature and clinical outcome in small cell lung cancer (SCLC). In nestin knock-down and overexpression cell lines, nesin expression was related to cell proliferation in vivo and resistance to anticancer drugs. In second-line chemotherapy, nestin-positive patients evaluated by immunohistochemistry of tumor specimens tended to have a lower disease control rate than negative. Furthermore, progression free survival was significantly shorter in nestin-positive patients. Our results suggest that nestin expression lead to resistance to chemotherapy and worse outcome in SCLC patients.

Free Research Field

呼吸器内科